Milestone Pharmaceuticals - Common Shares (MIST) closed at $0.70 on October 19, 2026, down 1.0% from the previous close, on volume of 649,790 shares (30-day average 1,285,990).
Data as of October 19, 2026.
19-Oct-2026
Milestone Pharmaceuticals Announces Clinical Data Presentations at Upcoming Cardiology Conferences
Globe Newswire (Mon, 19-Oct 8:00 AM ET)
Globe Newswire (Fri, 9-Oct 8:00 AM ET)
Globe Newswire (Thu, 24-Sep 8:00 AM ET)
Globe Newswire (Thu, 3-Sep 9:35 AM ET)
Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
Globe Newswire (Wed, 2-Sep 8:00 AM ET)
Globe Newswire (Thu, 27-Aug 8:00 AM ET)
Globe Newswire (Fri, 21-Aug 8:00 AM ET)
Globe Newswire (Wed, 12-Aug 7:08 AM ET)
Milestone Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 12, 2026
Globe Newswire (Tue, 4-Aug 4:01 PM ET)
Milestone’s CARDAMYST Approval Delivers First Self-Administered PSVT Solution in Over 30 Years
Market Chameleon (Mon, 15-Dec 4:55 AM ET)
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.
Milestone Pharmaceuticals - Common Shares trades on the NASDAQ stock market under the symbol MIST.
As of October 19, 2026, MIST stock price declined to $0.70 with 649,790 million shares trading.
MIST has a beta of 3.57, meaning it tends to be more sensitive to market movements. MIST has a correlation of 0.27 to the broad based SPY ETF.
MIST has a market cap of $87.16 million. This is considered a Micro Cap stock.
Last quarter Milestone Pharmaceuticals - Common Shares reported $559,000 in Revenue and -$.21 earnings per share. This fell short of revenue expectation by $-254,336 and missed earnings estimates by -$.02.
In the last 3 years, MIST traded as high as $3.52 and as low as $.63.
The top ETF exchange traded funds that MIST belongs to (by Net Assets): GWX.
MIST has underperformed the market in the last year with a price return of -64.5% while the SPY ETF gained +17.2%. MIST has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -43.5% and -13.5%, respectively, while the SPY returned +2.4% and -0.4%, respectively.
MIST support price is $.67 and resistance is $.75 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MIST shares will trade within this expected range on the day.
